- Home
- BCTX vs WIMI Comparison
BCTX vs WIMI Comparison
Compare BCTX & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- WIMI
- Stock Information
- Founded
- BCTX 2014
- WIMI 2015
- Country
- BCTX Canada
- WIMI China
- Employees
- BCTX N/A
- WIMI 107
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- WIMI Computer Software: Prepackaged Software
- Sector
- BCTX Health Care
- WIMI Technology
- Exchange
- BCTX Nasdaq
- WIMI Nasdaq
- Market Cap
- BCTX 23.5M
- WIMI 23.9M
- IPO Year
- BCTX N/A
- WIMI 2020
- Fundamental
- Price
- BCTX $3.11
- WIMI $2.96
- Analyst Decision
- BCTX Strong Buy
- WIMI
- Analyst Count
- BCTX 1
- WIMI 0
- Target Price
- BCTX $32.00
- WIMI N/A
- AVG Volume (30 Days)
- BCTX 359.2K
- WIMI 7.6M
- Earning Date
- BCTX 06-16-2025
- WIMI 01-01-0001
- Dividend Yield
- BCTX N/A
- WIMI N/A
- EPS Growth
- BCTX N/A
- WIMI N/A
- EPS
- BCTX N/A
- WIMI N/A
- Revenue
- BCTX N/A
- WIMI $84,137,968.00
- Revenue This Year
- BCTX N/A
- WIMI N/A
- Revenue Next Year
- BCTX N/A
- WIMI N/A
- P/E Ratio
- BCTX N/A
- WIMI N/A
- Revenue Growth
- BCTX N/A
- WIMI 19.25
- 52 Week Low
- BCTX $2.78
- WIMI $0.27
- 52 Week High
- BCTX $29.40
- WIMI $2.92
- Technical
- Relative Strength Index (RSI)
- BCTX 44.63
- WIMI 48.80
- Support Level
- BCTX $2.78
- WIMI $2.38
- Resistance Level
- BCTX $3.16
- WIMI $2.63
- Average True Range (ATR)
- BCTX 0.19
- WIMI 0.22
- MACD
- BCTX -0.01
- WIMI 0.14
- Stochastic Oscillator
- BCTX 40.24
- WIMI 86.89
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.